Altocor

This page contains recent news articles, when available, and an overview of Altocor but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

Overview:

Altocor (when available)

Pharmacology and use:
Lovastatin, an antilipemic agent produced by fermentation of Aspergillus terreus, is the first of a class of lipid-lowering agents known as the HMG-CoA reductase inhibitors. Lovastatin is used to treat hypercholesterolemia, to slow coronary atherosclerosis, and to prevent myocardial infarction and stroke. Lovastatin, like simvastin and unlike pravastatin, is a prodrug, concentrating active drug in the liver during first-pass circulation. For management as an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels in patients with primary hypercholesterolemia and mixed dyslipidemia; For primary prevention of coronary heart disease

Mechanism Of Action:
Lovastatin is a lactone that is readily hydrolyzed in vivo to the corresponding b-hydroxyacid, a potent inhibitor of HMG-CoA reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate. The conversion of HMG-CoA to mevalonate is an early step in the biosynthetic pathway for cholesterol.

News Articles on Lovastatin

Brand Names/Synonyms:
Altocor is also known by the following brand names and/or synonyms6alpha-Methylcompactin; Altocor; Altoprev; Artein; Belvas; Cholestra; Closterol; Colevix; Compactin; HSDB 6534; Hipolip; Hipovastin; Lestatin; Lipdip; Lipivas; Lipofren; Lovalip; Lovalord; Lovastatin; Lovastatin [Usan:Ban:Inn]; Lovastatina [Spanish]; Lovastatine [French]; Lovastatinum [Latin]; Lovasterol; Lovastin; Lozutin; MK 803; MK-803; ML-530B; MSD 803; Mevacor; Mevastatin; Mevinacor; Mevinolin; Mevlor; Monacolin K; Nergadan; Paschol; Pravastatin; Rodatin; Rovacor; Sivlor; Taucor; Tecnolip; Teroltrat

Drug Category:
Altocor is categorized under the following by the FDA: Antineoplastic Agents; Anticholesteremic Agents; HMG-CoA Reductase Inhibitors; ATC:C10AA02

Dosage Forms:
Tablet

Absorption:
30%

Interactions:
[an error occurred while processing this directive]

Chemical IUPAC Name:
[8-[2-(4-hydroxy-6-oxo-oxan-2-yl)ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2-methylbutanoate

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on cancernewsnetwork.org lead to other sites. cancernewsnetwork.org does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is CancerNewsNetwork.org responsible for dead or misdirected links.

IF YOU NEED A LINK OR TEXT REMOVED FROM THIS PAGE PLEASE CONTACT cancernewsnetwork (at) live.com.
We will do our best to accommodate your request.